Cargando…

Rimonabant, Gastrointestinal Motility and Obesity

BACKGROUND: Obesity and overweight affect more than half of the US population and are associated with a number of diseases. Rimonabant, a cannabinoid receptor 1 blocker in the endocannabinoid (EC) system, was indicated in Europe for the treatment of obesity and overweight patients with associated ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yan, Chen, Jiande
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3468875/
https://www.ncbi.nlm.nih.gov/pubmed/23449551
http://dx.doi.org/10.2174/157015912803217297